---
schema_version: "secwatch.filing_event.v1"
accession: "0001764013-22-000139"
form_type: "8-K"
ticker: "IMVT"
cik: "0001764013"
company_name: "Immunovant, Inc."
filed_at: "2022-11-04T23:59:59+00:00"
generated_at: "2026-06-22T07:11:18.500971+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Immunovant unveils next-gen FcRn inhibitor IMVT-1402; Q2 net loss $47.9M

## Summary
- IMVT-1402 observed in animal study to have best-in-class IgG reduction with minimal albumin/LDL impact.
- New batoclimab programs: Phase 2b in CIDP (start by end-2022) and Phase 2 in Graves' disease (early 2023).
- Pro forma cash $476M after $70M October 2022 equity offering; cash runway into H2 2025.
- Q2 net loss $47.9M ($0.41/sh) vs $37.7M ($0.35/sh) YoY; R&D expenses rose to $37.7M.
- IMVT-1402 IND submission early 2023, initial data mid-2023; batoclimab MG and TED trials on track.

## SEC filing metadata
- accession: 0001764013-22-000139
- form_type: 8-K
- ticker: IMVT
- cik: 0001764013
- company_name: Immunovant, Inc.
- filed_at: 2022-11-04T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1764013/000176401322000139/0001764013-22-000139-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1764013/000176401322000139/imvt-20221104.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001764013-22-000139
- JSON: https://secwatch.observer/filing/0001764013-22-000139.json
- Plain text: https://secwatch.observer/filing/0001764013-22-000139.txt

## Key facts
- Earnings Releases
  Immunovant, Inc. reported its fiscal second quarter and six months ended September 30, 2022 results: net income Net loss was $88.3 million ($0.76 per common share) for the six months ended September 30, 2022, EPS $0.76 per common share.
  - Period: its fiscal second quarter and six months ended September 30, 2022
  - Net income: Net loss was $88.3 million ($0.76 per common share) for the six months ended September 30, 2022
  - EPS: $0.76 per common share
  - Result: reported results
  source text: Net loss was $47.9 million ($0.41 per common share) for the three months ended September 30, 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1764013/000176401322000139/0001764013-22-000139-index.htm
- Earnings Releases
  Immunovant, Inc. reported its fiscal second quarter and six months ended September 30, 2022 results: net income Net loss was $88.3 million ($0.76 per common share) for the six months ended September 30, 2022, EPS $0.76 per common share.
  - Period: its fiscal second quarter and six months ended September 30, 2022
  - Net income: Net loss was $88.3 million ($0.76 per common share) for the six months ended September 30, 2022
  - EPS: $0.76 per common share
  - Result: reported results
  source text: Net loss was $88.3 million ($0.76 per common share) for the six months ended September 30, 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1764013/000176401322000139/0001764013-22-000139-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.